Other languages Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Real-time Estimate Cboe BZX Other stock markets 09:36:51 2024-04-30 am EDT			5-day change	1st Jan Change
0.491 ^USD	+1.85%		-0.60%	-7.71%

Mar. 25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	Feb. 01
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	Jan. 31
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Kiora Pharmaceuticals, Inc. Announces Board Changes	23-09-21
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director	23-08-01
Kiora Pharmaceuticals, Inc. Enters into an Intellectual Property License Agreement with Sentrx Animal Care, Inc	23-06-15
Sector Update: Health Care Stocks Rising Late Friday	23-06-02
Sector Update: Health Care Stocks Rising Friday Afternoon	23-06-02
Top Midday Decliners	23-06-02
Kiora Pharmaceuticals Prices $5.5 Million Public Offering; Shares Drop	23-06-02
Top Premarket Decliners	23-06-02
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Kiora Pharmaceuticals Presents Preliminary Results from an Ongoing Clinical Trial Showing its Investigational Drug, KIO-301	23-04-27
Kiora Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-22
Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301	23-02-14
Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases	23-02-07
Kiora Pharmaceuticals Completes Enrollment in Eye Therapy KIO-201 Study	23-01-03
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kiora Pharmaceuticals, Inc.

Equities

KPRX

US49721T3095

Other languages

Filters